Two opposing analyst actions (Overweight reaffirmation vs. Neutral downgrade) tied to ongoing trial/competition implications are likely to influence sentiment and near-term price action, though without a new company event like earnings or data release.
Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments Sheryar Siddiq Tue, June 2, 2026 at 11:37 AM GMT+2 1 min read SMMT Summit Therapeutics Inc. (NASDAQ: SMMT ) ranks among the best short squeeze stocks to invest in . On May 22, Cantor Fitzgerald restated its Overweight rating for Summit Therapeutics Inc.
(NASDAQ:SMMT). The firm addressed concerns about the HARMONi-3 trial, which is evaluating ivonescimab in first-line squamous non-small cell lung cancer. The trial failed to meet an interim progression-free survival threshold, increasing investor doubts regarding its efficacy in comparison to data from HARMONi-6, a China-exclusive trial.
Cantor Fitzgerald reported that medical professionals were less deterred by the interim progression-free survival shortfall. The expert opinion was influenced by the firm’s low alpha spend and the fact that the analysis was performed very early. Meanwhile, H.
C. Wainwright downgraded Summit Therapeutics Inc. (NASDAQ:SMMT) to Neutral from Buy, noting competition from Merck’s sacituzumab tirumotecan results.
The firm stated that sacituzumab tirumotecan, coupled with pembrolizumab, had an immature overall survival hazard ratio of 0. 55, which might place strain on Summit’s ivonescimab if the trend continues with prolonged follow-up. Summit Therapeutics Inc.
(NASDAQ:SMMT) is a biopharmaceutical firm. The company’s main product, Ridinilazole, is an orally administered small-molecule antibiotic now in Phase III clinical trials to treat CDI. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News .
Oraklio AI Trading Intelligence
Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.
Get started freeAlready have an account? Sign in →